GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells And The Pathogenesis Of Idiopathic Pulmonary Fibrosis At The 2023 Pittsburgh-Ireland International Lung Conference
Portfolio Pulse from Benzinga Newsdesk
GRI Bio has presented translational data demonstrating a connection between NKT cells and the pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference. The company is on track to launch a Phase 2a biomarker study for its lead program, GRI-0621, a type 1 invariant NKT (iNKT) antagonist for the treatment of IPF, before the end of the year.
October 19, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GRI Bio's new data and upcoming Phase 2a study for GRI-0621 could potentially boost the company's stock in the short term.
The presentation of positive data and the upcoming launch of a Phase 2a study for GRI-0621, a potential treatment for IPF, could generate investor interest and positively impact GRI Bio's stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100